TY - JOUR
T1 - Saffron for treatment of fluoxetine-induced sexual dysfunction in women
T2 - Randomized double-blind placebo-controlled study
AU - Kashani, Ladan
AU - Raisi, Firoozeh
AU - Saroukhani, Sepideh
AU - Sohrabi, Hamid
AU - Modabbernia, Amirhossein
AU - Nasehi, Abbas Ali
AU - Jamshidi, Amirhossein
AU - Ashrafi, Mandana
AU - Mansouri, Parisa
AU - Ghaeli, Padideh
AU - Akhondzadeh, Shahin
PY - 2013/1
Y1 - 2013/1
N2 - Objective Saffron (Crocus sativus L.) has shown beneficial aphrodisiac effects in some animal and human studies. The aim of the present study was to assess the safety and efficacy of saffron on selective serotonin reuptake inhibitor-induced sexual dysfunction in women. Methods This was a randomized double-blind placebo-controlled study. Thirty-eight women with major depression who were stabilized on fluoxetine 40 mg/day for a minimum of 6 weeks and had experienced subjective feeling of sexual dysfunction entered the study. The patients were randomly assigned to saffron (30 mg/daily) or placebo for 4 weeks. Measurement was performed at baseline, week 2, and week 4 using the Female Sexual Function Index (FSFI). Side effects were systematically recorded. Results Thirty-four women had at least one post-baseline measurement and completed the study. Two-factor repeated measure analysis of variance showed significant effect of time × treatment interaction [Greenhouse-Geisser's corrected: F(1.580, 50.567) = 5.366, p = 0.012] and treatment for FSFI total score [F(1, 32) = 4.243, p = 0.048]. At the end of the fourth week, patients in the saffron group had experienced significantly more improvement in total FSFI (p < 0.001), arousal (p = 0.028), lubrication (p = 0.035), and pain (p = 0.016) domains of FSFI but not in desire (p = 0.196), satisfaction (p = 0.206), and orgasm (p = 0.354) domains. Frequency of side effects was similar between the two groups. Conclusions It seems saffron may safely and effectively improve some of the fluoxetine-induced sexual problems including arousal, lubrication, and pain.
AB - Objective Saffron (Crocus sativus L.) has shown beneficial aphrodisiac effects in some animal and human studies. The aim of the present study was to assess the safety and efficacy of saffron on selective serotonin reuptake inhibitor-induced sexual dysfunction in women. Methods This was a randomized double-blind placebo-controlled study. Thirty-eight women with major depression who were stabilized on fluoxetine 40 mg/day for a minimum of 6 weeks and had experienced subjective feeling of sexual dysfunction entered the study. The patients were randomly assigned to saffron (30 mg/daily) or placebo for 4 weeks. Measurement was performed at baseline, week 2, and week 4 using the Female Sexual Function Index (FSFI). Side effects were systematically recorded. Results Thirty-four women had at least one post-baseline measurement and completed the study. Two-factor repeated measure analysis of variance showed significant effect of time × treatment interaction [Greenhouse-Geisser's corrected: F(1.580, 50.567) = 5.366, p = 0.012] and treatment for FSFI total score [F(1, 32) = 4.243, p = 0.048]. At the end of the fourth week, patients in the saffron group had experienced significantly more improvement in total FSFI (p < 0.001), arousal (p = 0.028), lubrication (p = 0.035), and pain (p = 0.016) domains of FSFI but not in desire (p = 0.196), satisfaction (p = 0.206), and orgasm (p = 0.354) domains. Frequency of side effects was similar between the two groups. Conclusions It seems saffron may safely and effectively improve some of the fluoxetine-induced sexual problems including arousal, lubrication, and pain.
KW - Crocus sativus L
KW - SSRI
KW - fluoxetine
KW - saffron
KW - sexual dysfunction
KW - women
UR - http://www.scopus.com/inward/record.url?scp=84873099006&partnerID=8YFLogxK
U2 - 10.1002/hup.2282
DO - 10.1002/hup.2282
M3 - Article
C2 - 23280545
AN - SCOPUS:84873099006
SN - 0885-6222
VL - 28
SP - 54
EP - 60
JO - Human Psychopharmacology
JF - Human Psychopharmacology
IS - 1
ER -